Coherus BioSciences
333 Twin Dolphin Dr, #600
Redwood City
CA
94065
United States
Tel: 800-794-5434
Website: https://www.coherus.com/
About Coherus BioSciences
We are committed to making high-value biosimilars affordable for everyone. It’s an unconventional approach to business that defines who we are and what we do.
At Coherus, we hold ourselves to a higher standard. We don’t break the rules—we write our own.
In early 2021, we expanded our mission into immuno-oncology with a collaboration with Shanghai Junshi Biosciences for the development and commercialization of toripalimab, Junshi Biosciences’ novel anti-PD-1 antibody, in the United States and Canada.
We are embarking on a new phase in our evolution, focused on expanding patient access to important, cost-effective medicines and delivering significant savings to the U.S. healthcare system. Join us, as we seek to break down barriers and make a difference in patients’ lives.
Stock Symbol: CHRS
Stock Exchange: NASDAQ
191 articles with Coherus BioSciences
-
Coherus BioSciences Appoints Dr. Jill O’Donnell-Tormey to its Board of Directors
5/11/2022
Coherus Biosciences, Inc. announced the appointment of cancer immunotherapy leader Jill O’Donnell-Tormey, Ph.D., to its Board of Directors.
-
Coherus BioSciences Management to Present at Upcoming Investor Conferences
5/10/2022
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), announced today that senior management will present at the following investor conferences in May. BofA Securities 2022 Healthcare Conference on Thursday, May 12 at 3:00 p.m. ET UBS Global Healthcare Conference on Tuesday, May 24 at 2:00 p.m. ET.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Coherus BioSciences Reports First Quarter 2022 Results
5/5/2022
Coherus BioSciences, Inc., reported financial results for the quarter ended March 31, 2022 and recent business highlights.
-
Coherus BioSciences Appoints Charlie Newton to Board of Directors
5/5/2022
Coherus BioSciences, Inc. today announced the appointment of former investment banker and renowned biotech strategist Charlie Newton to its Board of Directors.
-
Coherus BioSciences Announces New Employment Inducement Grants - May 04, 2022
5/4/2022
Coherus BioSciences, Inc., announced that effective April 27, 2022, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 240,000 shares of the common stock of the Company to 13 newly hired employees with a per share exercise price of $9.28, the closing trading price on the grant date.
-
The FDA is quickly catching up after COVID-19 disrupted typical review timelines and planned inspections and Monday morning held bad news for Coherus, Junshi and Axsome.
-
Junshi Biosciences and Coherus Receive Complete Response Letter from U.S. FDA for Toripalimab BLA
5/2/2022
Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”) announced today that the U.S. Food and Drug Administration (“FDA”, “the Agency”) has issued a complete response letter (“CRL”) for the Biologics License Application (“BLA”).
-
Coherus and Junshi Biosciences Receive Complete Response Letter from U.S. FDA for Toripalimab BLA
5/2/2022
Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, “Junshi”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) announced today that the U.S. Food and Drug Administration (“FDA”, “the Agency”) has issued a complete response letter (“CRL”) for the Biologics License Application (“BLA”) for toripalimab in combination with gemcitabine and cisplatin.
-
Coherus BioSciences to Report First Quarter 2022 Financial Results on May 5th, 2022
4/29/2022
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its first quarter 2022 financial results will be released after the close of the United States financial markets on Thursday, May 5th, 2022.
-
Bristol Myers Squibb will hear from the FDA on April 28 about Mavacamten, while Supernus, Axsome, Coherus, Hutchmed and Incyte also await the fate of their respective drug candidates.
-
Junshi Biosciences and Coherus Announce PD-1 Inhibitor Toripalimab Granted Orphan Drug Designation for Small Cell Lung Cancer in the United States
4/14/2022
Shanghai Junshi Biosciences Co., Ltd. and Coherus BioSciences, Inc. announced today that the United States Food and Drug Administration ("FDA") has granted Orphan Drug Designation (“ODD”) for toripalimab, a PD-1 inhibitor, for the treatment of small cell lung cancer (“SCLC”).
-
Coherus and Junshi Biosciences Announce PD-1 Inhibitor Toripalimab Granted Orphan Drug Designation for Small Cell Lung Cancer in the United States
4/14/2022
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced today that the United States Food and Drug Administration ("FDA") has granted Orphan Drug Designation (“ODD”) for toripalimab, a PD-1 inhibitor, for the treatment of small cell lung cancer (“SCLC”).
-
Junshi Biosciences and Coherus Present Results of Phase 3 Study of Toripalimab in First Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at 2022 AACR Annual Meeting
4/9/2022
Shanghai Junshi Biosciences Co., Ltd and Coherus BioSciences, Inc. announced the results of the prespecified final progression-free survival analysis and the interim overall survival analysis of the JUPITER-02 study, a pivotal Phase 3 trial in first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.
-
Coherus and Junshi Biosciences Present Results of Phase 3 Study of Toripalimab in First Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at 2022 AACR Annual Meeting
4/8/2022
Shanghai Junshi Biosciences Co., Ltd and Coherus BioSciences, Inc. announced the results of the prespecified final progression-free survival analysis and the interim overall survival analysis of the JUPITER-02 study, a pivotal Phase 3 trial in first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.
-
Coherus BioSciences Announces New Employment Inducement Grants - Apr 05, 2022
4/5/2022
Coherus BioSciences, Inc., announced that effective March 31, 2022, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 461,000 shares of the common stock of the Company to newly hired employees with a per share exercise price of $12.91, the closing trading price on the grant date.
-
Coherus Highlights Anticipated New Product Launches and Immuno-oncology Growth Strategy at Analyst Day Event
3/29/2022
Coherus BioSciences, Inc., beginning at 9:30 a.m. Eastern Daylight Time , is hosting a meeting with analysts and investors to present the Company’s corporate strategy to build a leading innovative immuno-oncology franchise funded with cash generated through net sales of its diversified portfolio of FDA-approved therapeutics.
-
Coherus BioSciences to Highlight New Product Pipeline, Cancer Immunotherapy Development Plans at March 29, 2022 Analyst Day Event
3/22/2022
Coherus BioSciences, Inc. today announced that Coherus plans to host an Analyst Day on March 29, 2022 at 9:30 a.m. ET in New York City.
-
Biopharma and life sciences companies continue to strengthen their executive teams and boards with this week’s Movers & Shakers.
-
Junshi Biosciences and Coherus Announce Presentation of Positive Results from CHOICE-01
3/15/2022
Shanghai Junshi Biosciences Co., and Coherus Biosciences today announced the presentation of positive results and biomarker analyses from the pivotal study “CHOICE-01” (clinicaltrials.gov identifier# NCT03856411).